Gene Center Munich

Breadcrumb Navigation


Subklewe Lab - Translational Cancer Immunology

Research Topics

  • Novel Target Antigens
  • Antibodies + CAR-T Cells
  • Vaccination + Checkpoint Blockade
  • Immune Monitoring + Biomarkers

Prof. Marion Subklewe

phone: +49 (0)89 - 4400 73133

The Laboratory for Translational Cancer Immunology develops immunotherapies for malignant neoplasia, with a special focus on acute leukemia and B-cell lymphoma. We seek to understand mechanisms of action and resistance of cellular- and antibody-based immunotherapy. The goal is to identify predictive biomarkers for selecting the suitable immunotherapy for each individual patient. Read more...

Selected Publications

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Köhnke T, Vick B, Jeremias I, Metzeler KH, Altmann T, Schneider S, Fiegl M, Spiekermann K, Bauerle PA, Hiddemann W, Riethmüller G, Subklewe M.
Leukemia. 2016 Feb;30(2):484-91. doi: 10.1038/leu.2015.214. Epub 2015 Aug 4. PubMed

Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.
Köhnke T, Sauter D, Ringel K, Hoster E, Laubender RP, Hubmann M, Bohlander SK, Kakadia PM, Schneider S, Dufour A, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Spiekermann K, Subklewe M.
Leukemia. 2015 Feb;29(2):377-86. doi: 10.1038/leu.2014.186. Epub 2014 Jun 10. PubMed

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, Spiekermann K, Baeuerle PA, Hiddemann W, Riethmüller G, Subklewe M.
Blood. 2014 Jan 16;123(3):356-65. doi: 10.1182/blood-2013-08-523548. Epub 2013 Dec 3. PubMed

Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission.
Beck B, Dörfel D, Lichtenegger FS, Geiger C, Lindner L, Merk M, Schendel DJ, Subklewe M.
J Transl Med. 2011 Sep 13;9:151. doi: 10.1186/1479-5876-9-151. PubMed

More publications